Deere, CNH and AGCO Stocks Fall as FTC Launches Farm Equipment Probe 
Bangladesh GDP Growth Accelerates to 4.6% on Industrial Rebound 
France to Release 10 Million Barrels of Diesel to Ease Fuel Prices 
Asian Currencies Mixed as Yen Weakens, Dollar Holds Firm 
Asian Currencies Steady as Dollar Eyes Fourth Weekly Gain 
Zcash Plans Quantum-Resistant Security Upgrade for January 
US Dollar Rises for Fourth Week as Fed Rate Hike Bets Grow 
Wall Street Falls as Oil Prices Rise and Tech Stocks Slide 
TSMC Q3 Revenue Beats Estimates as AI Chip Demand Surges 
Asian Stocks Mixed as OpenAI Revenue Concerns Hit Chipmakers 
Mike Rogers Calls for End to US-Canada Tariff War 
Oil Prices Trim Gains After Trump Rules Out Iran Strikes Before Midterms 
Gold Prices Rise as Hormuz Tensions Fuel Inflation Risks 
US Dollar Hits 18-Month High as Fed Signals More Rate Hikes 
Oil Prices Rise as Hormuz Risks Offset IEA Stock Release 
US Stock Futures Flat as Fed Minutes, Earnings Loom 
Dollar Near 18-Month High as Euro, Yen and Pound Weaken 
Add as a preferred source on Google
SK Holdings revealed its acquisition of a French drug-maker called Yposkesi this week. The third-largest conglomerate in South Korea made the purchase in its bid to strengthen its competitive power in the global market’s biotech sector.
Moreover, SK has acquired French drug manufacturer Yposkesi to expand into the rapidly growing contract manufacturing organization (CMO) business, the newly renamed holding company of SK Group said Wednesday.
SK completed the acquisition
The Korea Times reported that SK acquired 70% percent shares, and this includes management rights in the French company. The acquisition came four months after the South Korean company said it is in talks to purchase Yposkesi.
The price of the deal was not mentioned in the reports, so there is no clear figure how much SK shelled out for the acquisition. The deal has been completed, and Yposkesi will now be operated by SK Pharmteco, a CMO subsidiary owned by SK Inc. based in Sacramento.
"We are glad to advance into the gene therapy CMO business by investing in Yposkesi which has great capability and potential," Jang Dong Kyun, SK’s chief executive officer, said. "We will spare no efforts to help Yposkesi grow fast in the global market."
About Yposkesi
Yposkesi, the French cell, and gene therapy company, is also one of the largest Contract Development & Manufacturing Organizations (CDMO) in Europe. With the purchase of this company, SK will now be able to supply innovative drugs around the world through creating a contract manufacturing organization (CMO) business system, as per Aju Business Daily.
Yposkesi was launched in 2016 by AFM-Téléthon and by the SPI fund managed by Bpifrance. It is the first French firm to develop and produce gene and cell therapy products. The company’s goal is to create the first treatments available to patients then sell them for a fair price.
Meanwhile, this is SK Holding’s third acquisition deal in the global CMO industry as it aims to be one of the best players in the biotechnology industry. Its purchase of pharma and biotech companies shows its determination to rise above in the market for this field.
"SK plans to complete the value chain of its synthetic and biopharmaceutical CMO business in the U.S., Europe and Asia by 2025," SK’s head in bio investment center, Lee Dong Hoon, said. "We will foster SK Pharmteco as a global leading CMO that can supply synthetic, gene and cell therapy drugs to the global pharmaceutical market."
